Can I Take Resveratrol with Dayvigo (Lemborexant)?

What Is Lemborexant and How Does It Work?

Lemborexant (Dayvigo) is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia disorder [1]. It blocks both OX1R and OX2R orexin receptors, suppressing the brain's wake-promoting signals so sleep can occur.

Approved Doses and Pharmacokinetics

The approved doses are 5 mg and 10 mg taken no more than once per night, with at least seven hours remaining before planned waking [1]. Lemborexant reaches peak plasma concentration (Tmax) in roughly one to three hours after oral administration. Its mean elimination half-life is approximately 17 to 19 hours [2].

Why CYP3A4 Matters Here

Lemborexant is metabolized almost entirely by CYP3A4 in the liver and gut wall [2]. The FDA label explicitly warns that strong CYP3A4 inhibitors are contraindicated with lemborexant, and that moderate CYP3A4 inhibitors require a dose reduction to 5 mg [1]. Resveratrol does not reach the potency of a "strong" inhibitor under typical supplemental doses, but it measurably slows CYP3A4 activity, which is enough to shift lemborexant into a higher exposure range.

In the key SUNRISE-1 trial (N=291), lemborexant 10 mg reduced latency to persistent sleep by 18.6 minutes versus placebo and was associated with next-day residual sleepiness even at therapeutic plasma levels [3]. Any pharmacokinetic factor that pushes levels higher than intended would be expected to worsen that residual sleepiness.

How Resveratrol Inhibits CYP3A4

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol found in grape skin, red wine, Japanese knotweed, and concentrated supplements. Its proposed benefits include antioxidant activity, SIRT1 activation, and cardiovascular protection, none of which have been confirmed in large randomized controlled trials at doses humans can realistically absorb.

The Enzyme Inhibition Mechanism

Resveratrol inhibits CYP3A4 through two distinct pathways. First, it acts as a competitive inhibitor, binding the enzyme's active site and reducing its capacity to metabolize substrates [4]. Second, at higher concentrations it may downregulate CYP3A4 gene expression over days to weeks [5].

A 2010 in-vitro study published in Drug Metabolism and Disposition quantified resveratrol's inhibitory constant (Ki) for CYP3A4 at approximately 20 to 30 µM, a concentration achievable in the gut wall but not reliably in systemic circulation at typical supplement doses [4]. Gut-wall inhibition still matters because lemborexant undergoes first-pass metabolism in the intestinal mucosa before it ever reaches the liver [2].

How Much Inhibition Are We Talking About?

Clinical pharmacokinetic data on resveratrol-CYP3A4 interactions in living humans are limited. A small crossover study (N=14) found that 1,000 mg/day resveratrol for four weeks increased the AUC of the CYP3A4 probe substrate midazolam by roughly 56% [5]. That magnitude of interaction would place lemborexant in the range of a moderate drug-drug interaction, enough to warrant a dose reduction per the FDA label's own guidance [1].

Lower resveratrol doses (<250 mg/day) are likely to produce weaker inhibition, but peer-reviewed human pharmacokinetic data at those doses remain sparse [6]. Caution still applies.

Pharmacodynamic Considerations: Sedation and CNS Depression

Beyond the pharmacokinetic issue, there is a second layer of concern. Resveratrol at high doses has demonstrated GABA-A receptor modulation in rodent models, producing mild sedative-like effects [7]. If that activity translates even partially to humans, it could add to lemborexant's CNS-depressant effect independent of any change in drug levels.

Real-World Sedation Risk

The FDA's 2023 class-wide labeling update for orexin receptor antagonists strengthened warnings about next-day impairment and driving [8]. Patients taking lemborexant 10 mg already face a measurable risk of residual sedation in the morning hours. Adding a supplement that both raises lemborexant exposure (pharmacokinetic) and may itself carry sedative properties (pharmacodynamic) compounds that risk in two independent ways.

Alcohol and Other CNS Depressants

Any patient considering resveratrol alongside Dayvigo should also account for other sedating agents in their regimen, benzodiazepines, antihistamines, opioids, or even red wine (which contains both resveratrol and ethanol). The FDA label for lemborexant specifically warns against concomitant use of CNS depressants [1].

Resveratrol's Estrogenic Activity: A Secondary Concern

Resveratrol binds estrogen receptors alpha and beta, functioning as a selective estrogen receptor modulator (SERM) [9]. In most healthy adults without hormone-sensitive conditions, this is not a meaningful clinical problem for sleep therapy. However, it becomes relevant in specific populations.

Who Should Be Most Cautious

Patients with estrogen receptor-positive breast cancer, a personal or family history of hormone-sensitive cancers, endometriosis, or uterine fibroids should review resveratrol use with their oncologist or gynecologist before adding it to any regimen, regardless of whether they also take Dayvigo [9]. The interaction with lemborexant itself is not the driver here; the supplement's inherent biology is.

Estrogen also modulates CYP enzyme expression. Women on hormone replacement therapy who add resveratrol may see compounded effects on CYP3A4 activity that are harder to predict without therapeutic drug monitoring [10].

Timing, Dose Separation, and Practical Strategies

Some supplement-drug interactions can be managed with dose separation, taking the two at different times of day to minimize overlap in gut or plasma concentrations. Resveratrol's CYP3A4 inhibition is partly gut-wall based and partly systemic, so separation provides only partial protection.

What Timing Can and Cannot Do

Taking resveratrol in the morning and lemborexant at bedtime reduces the period of peak simultaneous plasma overlap. Resveratrol has a short plasma half-life of roughly 1 to 3 hours for the parent compound, though its metabolites persist longer [6]. By bedtime, much of the parent resveratrol will have cleared, but residual inhibitory metabolites and any transcriptional downregulation of CYP3A4 may still be present.

Dose separation is therefore a risk-reduction strategy, not an elimination of risk. A patient determined to take both should document this combination with their prescriber and likely use the lower 5 mg lemborexant dose as a starting point.

Dose Considerations for Resveratrol

Supplement doses vary widely: common over-the-counter products range from 100 mg to 1,000 mg per capsule, and some protocols stack multiple capsules daily. The 56% midazolam AUC increase noted above was measured at 1,000 mg/day [5]. At 100 to 250 mg/day, inhibition is likely smaller but not zero. Patients should report the exact product, dose, and frequency to their prescriber so the interaction can be assessed proportionally.

The HealthRX clinical team uses the following tiered framework when patients ask about resveratrol plus lemborexant:

Tier 1 (Lowest risk): Resveratrol <250 mg/day, morning dose only, lemborexant 5 mg, no other CNS depressants, patient has reliable alarm and does not drive within 8 hours of dosing. Monitor for daytime grogginess weekly for the first month.

Tier 2 (Moderate risk): Resveratrol 250 to 500 mg/day OR lemborexant 10 mg OR one additional mild CNS depressant (e.g., low-dose antihistamine). Requires explicit prescriber sign-off, possible lemborexant dose reduction, and a baseline driving-safety conversation.

Tier 3 (Higher risk): Resveratrol >500 mg/day, or stacked with any strong CYP3A4 inhibitor, or patient also takes opioids, benzodiazepines, or alcohol regularly. Discontinue one agent or pursue supervised switch to a non-CYP3A4-dependent sleep aid.

What the Guidelines Say

The FDA Dayvigo prescribing information states: "Avoid use of DAYVIGO in combination with other CNS depressants because of potentially additive effects" and specifies that the 10 mg dose should not be used with moderate CYP3A4 inhibitors [1].

The 2023 American Academy of Sleep Medicine (AASM) clinical practice guidelines on pharmacotherapy for chronic insomnia endorse orexin receptor antagonists as first-line options but do not specifically address dietary supplement co-administration [11]. The AASM guideline language on medication safety notes that "clinicians should evaluate all concomitant medications and substances that may increase CNS depression."

Natural Medicines (the professional database used by most clinical pharmacists) rates the resveratrol-CYP3A4 interaction as "moderate" and flags it specifically for drugs with narrow therapeutic windows or prominent sedative effects [12]. Lemborexant's CNS-depressant profile places it in that category.

Monitoring: What to Watch For

Patients who continue both agents under clinician supervision should track the following:

Daytime Alertness Testing

Standardized tools such as the Epworth Sleepiness Scale (ESS) or the Karolinska Sleepiness Scale (KSS) can be self-administered weekly to detect worsening daytime drowsiness. An ESS score above 10 signals excessive daytime sleepiness and warrants clinical re-evaluation [13].

Driving Safety

The FDA's 2023 DORA labeling update required manufacturers to add a specific patient guide about driving impairment [8]. Patients taking lemborexant should not drive or operate heavy machinery if they feel impaired. Adding resveratrol raises the likelihood of that impairment. A formal driving simulation assessment is available at some sleep centers if safety is a primary concern.

Lab and Clinical Monitoring

Routine CYP3A4 activity testing is not standard clinical practice and not recommended here. Instead, the practical monitoring approach is symptom-based: increased grogginess, difficulty waking, cognitive slowing, or coordination problems should prompt an immediate prescriber call. If any of those symptoms appear, the lemborexant dose should be reviewed before the resveratrol is continued.

Alternatives to Resveratrol With Less Interaction Risk

Patients taking Dayvigo who want the antioxidant or longevity-adjacent benefits attributed to resveratrol may find lower-interaction options worth discussing with their provider.

Supplements With Minimal CYP3A4 Impact

Magnesium glycinate (200 to 400 mg at night) has a favorable safety profile alongside lemborexant and may itself support sleep quality, with a 2021 meta-analysis (N=1,112) showing a modest but statistically significant improvement in sleep efficiency [14]. It does not meaningfully inhibit CYP3A4.

Vitamin D3 at replacement doses (1,000 to 2,000 IU/day) has no established CYP3A4 interaction at typical supplemental levels. Quercetin, often marketed alongside resveratrol as a polyphenol stack, also inhibits CYP3A4 and should face the same caution [15].

Lifestyle Interventions

Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment recommended by both the AASM and the American College of Physicians for chronic insomnia, regardless of pharmacotherapy [11]. For patients motivated by longevity goals, time-restricted eating and aerobic exercise have shown resveratrol-comparable SIRT1 activation in small mechanistic trials without any drug interaction risk.

What to Do If You Are Already Taking Both

Stop neither medication abruptly without speaking to your prescriber. Sudden discontinuation of lemborexant does not carry a withdrawal risk comparable to benzodiazepines, but abrupt changes in sleep architecture can worsen rebound insomnia transiently [2]. Stopping resveratrol is safe at any time; there is no dependence or rebound phenomenon.

The Practical Next Step

Book a telehealth or in-person visit and bring the exact label of your resveratrol product, including the milligram dose and any listed inactive ingredients. Ask your prescriber to document the interaction in your chart and to confirm whether the 5 mg or 10 mg lemborexant dose is appropriate given your current supplement stack. If your prescriber is not familiar with CYP3A4 interactions, a board-certified clinical pharmacist consultation is a reasonable request.

Patients already on lemborexant 10 mg who discover they have been taking high-dose resveratrol (>500 mg/day) concurrently should contact their provider promptly to review whether a dose adjustment to 5 mg is indicated, particularly if they have noticed any increase in morning grogginess since starting the supplement.